Abstract |
IMPLICATIONS: Our work nominates a novel therapeutic strategy as well as its cellular mechanisms pertinent for future clinical trials combining M3814, radiation, and anti-PD-L1 antibody in patients with pancreatic cancer.
|
Authors | Weiwei Wang, Matthew T McMillan, Xinyi Zhao, Zhuwen Wang, Long Jiang, David Karnak, Fatima Lima, Joshua D Parsels, Leslie A Parsels, Theodore S Lawrence, Timothy L Frankel, Meredith A Morgan, Michael D Green, Qiang Zhang |
Journal | Molecular cancer research : MCR
(Mol Cancer Res)
Vol. 20
Issue 7
Pg. 1137-1150
(07 06 2022)
ISSN: 1557-3125 [Electronic] United States |
PMID | 35348737
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)
|
Copyright | ©2022 American Association for Cancer Research. |
Chemical References |
- Protein Kinase Inhibitors
- Pyridazines
- Quinazolines
- Protein Kinases
- DNA-Activated Protein Kinase
- RNA Polymerase III
- peposertib
|
Topics |
- DNA-Activated Protein Kinase
(antagonists & inhibitors)
- Humans
- Pancreatic Neoplasms
(drug therapy, immunology)
- Protein Kinase Inhibitors
(pharmacology)
- Protein Kinases
- Pyridazines
- Quinazolines
- RNA Polymerase III
|